Bavencio (avelumab)

February 14, 2020February 14, 2020

Checkpoint Inhibitor Combination Well-tolerated, Effective in Ovarian Cancer Patients, Phase 1b Trial Shows

News

A combination of two checkpoint inhibitor therapies, magrolimab (Hu5F9-G4) and Bavencio (avelumab), has an acceptable safety profile, is well-tolerated, and stabilizes disease in more than half of heavily-treated ovarian cancer ... Read more

February 6, 2019

Bavencio Shows Promise in Heavily Treated Ovarian Cancer Patients in Phase 1b Trial

News

Immune checkpoint inhibitor Bavencio (avelumab) has an acceptable safety profile and shows some anti-tumor activity among heavily pretreated ovarian cancer patients, according to a Phase 1b trial. Findings from the trial were reported ... Read more

December 10, 2018

Bavencio Fails to Meet Primary Objectives in Certain Ovarian Cancer Patients in Phase 3 Trial

News

The immune checkpoint inhibitor Bavencio (avelumab), with or without chemotherapy, is no better than chemotherapy alone at prolonging the lives of ovarian cancer patients who failed prior platinum-based chemotherapy, results from a Phase ... Read more